Teleflex (TFX)
Builds medical devices for vascular access, interventional, and surgical procedures.
Something off on this page? Send us feedback.
Develops medical devices for vascular access, interventional, and surgical markets. An acquisition added coronary and peripheral intervention capability, while announced sales of Acute Care, Interventional Urology, and OEM businesses remain pending closing.
Develops medical devices for vascular access, interventional, and surgical markets. Its acquisition of BIOTRONIK’s Vascular Intervention business added coronary and peripheral intervention capability.
The workforce spans the United States and 38 other countries, giving the company an international operating footprint. Its portfolio has been built through acquisitions and divestitures, including the earlier shift away from aerospace and commercial operations.
The business is in a further reset: announced sales of its Acute Care, Interventional Urology, and OEM businesses had not closed as of the latest context update. The stated remaining focus is vascular access, interventional, and surgical markets.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Aug 25, 2026 | Needham | Reiterate | Rating: —Target: $159 | Target: $170 |
| Aug 11, 2026 | UBS | Reiterate | Rating: —Target: $145 | Target: $158 |
| Aug 10, 2026 | Truist Financial | Target | Target: $135 | Target: $150 |
| Jul 31, 2026 | Needham | Reiterate | Rating: —Target: $147 | Target: $159 |
| Jul 28, 2026 | UBS | Initiate | Rating: —Target: — | Target: $145 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $300.2M · Total debt $2.87B · Total assets $6.79B · Shareholders' equity $2.90B
- Revenue
- $570.3M
- Operating income
- $60.3M
- Net income
- $102.0M
HistoryDividendAnnual yield
| Institutions | 114.42% | 48.48M shares | |
|---|---|---|---|
| 388 holders · as of Jun 30, 2026 | |||
| Insiders | 0.67% | 282.6K shares | |
| 19 holders · as of Sep 10, 2026 | |||
| Strategic holders | 10.25% | 4.34M shares | |
| 1 holder · as of Sep 8, 2026 | |||
| Adds to | 125.34% | ||
42.37M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
These groups come from separate filings that can overlap, so they add to 125.34%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
BlackRock, Inc.Institution | 12.82% | 5.43M | as of Jun 30, 2026 |
JANUS HENDERSON GROUP Ltd.Strategic | 10.25% | 4.34M | filed Sep 8, 2026 |
Jupiter Topco LLCInstitution | 10.25% | 4.34M | as of Jun 30, 2026 |
T. Rowe Price Investment Management, Inc.Institution | 7.54% | 3.19M | as of Jun 30, 2026 |
Vanguard Portfolio Management LLCInstitution | 5.70% | 2.42M | as of Jun 30, 2026 |
Insider tradesForm 4
No open-market trades in the last 12 months.
- BD
Broad vascular-access and peripheral-intervention hospital portfolio
- ICU Medical
Vascular-access consumables for hospital infusion and access care
- Boston Scientific
Coronary and peripheral vascular technologies for catheter-lab procedures
- Abbott
Large vascular portfolio for coronary and peripheral artery disease
- Medtronic
Scaled coronary and peripheral vascular medical-technology portfolio
- Merit Medical Systems
Vascular-access and cardiac/peripheral-intervention device specialist
- Johnson & Johnson
Surgical instrumentation, stapling and wound-closure product platform
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Teleflex | $124.27 | −0.42% | $5.52B | — | 13.4 | 2.1 | −27.0% |
| BD | $182.84 | +1.18% | $49.79B | 54.4 | 13.8 | 2.4 | −9.6% |
| ICU Medical | $160.82 | +3.61% | $3.88B | 131.5 | 18.1 | 1.8 | −0.2% |
| Boston Scientific | $44.76 | +2.37% | $64.98B | 17.8 | 13.6 | 3.1 | +7.5% |
| Abbott | $104.21 | +1.19% | $178.18B | 33.1 | 18.0 | 3.8 | +13.0% |
| Medtronic | $90.95 | −0.87% | $117.44B | 22.6 | 15.2 | 3.1 | +13.7% |
| Merit Medical Systems | $87.38 | +2.21% | $5.10B | 35.3 | 20.0 | 3.2 | +9.5% |
| Johnson & Johnson | $269.62 | +0.05% | $649.40B | 31.2 | 22.7 | 6.6 | +6.6% |
| Median | 33.1 | 18.0 | 3.1 | +7.5% |